Guidant gets FDA panel backing to use HF (heart failure) device more widely
This article was originally published in Clinica
Executive Summary
A US FDA advisory committee has proposed that the agency expand the indications for Guidant's cardiac resynchronisation therapy defibrillators (CRT-Ds), a move that would make the product line available to thousands of additional heart failure (HF) patients.